Comparing the development of mitral and tricuspid regurgitation between right ventricular apex and right ventricular outflow tract pacing

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103146061N1

Enrollment

164

Registered

2012-01-05

Start date

2010-11-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mitral Regurgitation. Mitral (valve): regurgitation NOS or of specified cause, except rheumatic

Interventions

Intervention 1: Contol group will receive Right Ventricular Apex (RVA) lead placement. Intervention 2: the intervention group will receive Right Ventricular Outflow Tract (RVOT).

Treatment - Devices

Contol group will receive Right Ventricular Apex (RVA) lead placement

the intervention group will receive Right Ventricular Outflow Tract (RVOT)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Adult patients with sick sinus syndrome or atrioventricular (AV) block who need to receive permanent pacemaker (PPM) implantation. Exclusion criteria: documented history of heart failure, valvular disease, or mitral/tricuspid regurgitation (MR and TR, respectively).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Development of Mitral valve regurgitation. Timepoint: at time 0 and 1 year after pacemaker implantation. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Tricuspid regurgitation. Timepoint: at time 0 and 1 year after implantation. Method of measurement: Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSevil Hemayat

Tehran Azad university of medical sciences

sevil.hemayat@gmail.com+98 21 6694 5488

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 21, 2026